Apex Biotechnology Corp.

TWSE:1733 Stock Report

Market Cap: NT$2.8b

Apex Biotechnology Balance Sheet Health

Financial Health criteria checks 6/6

Apex Biotechnology has a total shareholder equity of NT$1.8B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$2.3B and NT$557.6M respectively. Apex Biotechnology's EBIT is NT$119.0M making its interest coverage ratio 253.8. It has cash and short-term investments of NT$466.8M.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio253.8x
CashNT$466.79m
EquityNT$1.78b
Total liabilitiesNT$557.62m
Total assetsNT$2.34b

Recent financial health updates

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Recent updates

Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Nov 21
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21
Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17
Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10
Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17
Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27
A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22
Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Financial Position Analysis

Short Term Liabilities: 1733's short term assets (NT$1.6B) exceed its short term liabilities (NT$439.6M).

Long Term Liabilities: 1733's short term assets (NT$1.6B) exceed its long term liabilities (NT$118.0M).

Debt to Equity History and Analysis

Debt Level: 1733 is debt free.

Reducing Debt: 1733 has no debt compared to 5 years ago when its debt to equity ratio was 25.5%.

Debt Coverage: 1733 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1733 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y